Belantamab Mafodotin-Blmf: uses, dosing, side effects & brands
Belantamab Mafodotin-Blmf is a medicine sold in the U.S. under one brand, for multiple myeloma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Multiple Myeloma
- Available as
- Injectable
- Sold as
- Blenrep
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How belantamab mafodotin-blmf is dosed
From the FDA label for Blenrep (application BLA761440). Other belantamab mafodotin-blmf products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage of BLENREP, in combination with bortezomib and dexamethasone, is 2.5 mg/kg as an intravenous infusion over 30 minutes once every 3 weeks for 8 cycles, followed by BLENREP 2.5 mg/kg every 3 weeks as a single agent. ( 2.2 ) • See Full Prescribing Information for instructions on preparation and administration. ( 2.4 ) 2.1 Important Safety Information Ophthalmic exams, including slit lamp exam and assessment of best‑corrected visual acuity (BCVA), should be conducted by an eye care professional, such as an ophthalmologist or optometrist. Conduct ophthalmic exams at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated [see Warnings and Precautions ( 5.1 )]. Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Advise patients to use preservative‑free artificial tears at least 4 times a day starting with the first infusion and continuing until end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional [see Warnings and Precautions ( 5.1 )]. 2.2 Recommended Dosage The recommended dosage for BLENREP is 2.5 mg/kg of actual body weight once every 3 weeks in combination with bortezomib and dexamethasone (BVd) for the first 8 cycles, followed by BLENREP 2.5 mg/kg of actual…
Belantamab Mafodotin-Blmf side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: • Ocular Toxicity [see Warnings and Precautions ( 5.1 )] • Thrombocytopenia [see Warnings and Precautions ( 5.3 )] The most common adverse reactions (≥20%) with BLENREP in combination with bortezomib and dexamethasone are reduction in best-corrected visual acuity (BCVA), corneal exam findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, upper respiratory tract infection, hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract, and COVID-19. The most common Grade 3 or 4 (≥10%) laboratory abnormalities are decreased platelets, decreased lymphocytes, decreased neutrophils, increased gamma-glutamyl transferase, decreased white blood cells, and decreased hemoglobin. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. Relapsed or Refractory Multiple Myeloma in Combination with Bortezomib and Dexamethasone The safety of BLENREP with bortezomib and dexamethasone…
Who shouldn’t take belantamab mafodotin-blmf
None. None. ( 4 )
Every belantamab mafodotin-blmf product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Blenrep.
What people report to the FDA about belantamab mafodotin-blmf
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 3 reports naming belantamab mafodotin-blmf, and the FDA flagged 67% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- adverse drug reaction1 reports
- covid-191 reports
- infusion related reaction1 reports
- parainfluenzae virus infection1 reports
Read these as a signal, not a rate. A report does not mean belantamab mafodotin-blmf caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is belantamab mafodotin-blmf?
Belantamab mafodotin‑blmf is a B‑cell maturation antigen (BCMA)‑directed antibody and microtubule inhibitor conjugate.
Can you take belantamab mafodotin-blmf with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run belantamab mafodotin-blmf against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does belantamab mafodotin-blmf come in?
Across the brands we track, belantamab mafodotin-blmf is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic belantamab mafodotin-blmf?
We do not currently list a generic-labelled belantamab mafodotin-blmf product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Belantamab Mafodotin-Blmf: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/belantamab-mafodotin-blmf
- MLA
- “Belantamab Mafodotin-Blmf: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/belantamab-mafodotin-blmf.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for belantamab mafodotin-blmf on DailyMed (NIH) ↗ — including its boxed warning in full.